Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial

Documenti analoghi

• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  di: Soo Lim, et al.
  Pubblicazione: (2024)
• Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
  di: Kyung Ah Han, et al.
  Pubblicazione: (2024)
• Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
  di: Da Hea Seo, et al.
  Pubblicazione: (2025)
• VPO: Leveraging the Number of Votes in Preference Optimization
  di: Cho, Jae Hyeon, et al.
  Pubblicazione: (2024)
• Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial
  di: So Ra Kim, et al.
  Pubblicazione: (2026)